Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 12 and 17 years old at the time of their first study visit
- People who have atopic dermatitis (eczema) and have been prescribed dupilumab under the Italian medicines authority (AIFA) reimbursement rules
- People whose eczema severity score (EASI) is below 16, and who also meet at least one of the following: their quality of life score (CDLQI) is 10 or higher, their itch rating is 7 or higher on a scale of 0–10, or their eczema affects visible or sensitive areas such as the head, neck, hands, or genitals
- People who are able to understand and fill in study questionnaires
- People (or their parents or legal guardians) who have signed a consent form agreeing to take part
Who may not be able to join:
- People who have used dupilumab at any point in the 6 months before joining the study
- People who are currently taking part in another clinical trial that changes or affects their medical care
- People who have any condition that, in the opinion of the study doctor, might affect their ability to fully participate in the study (for example, substance use issues)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Sciences & Operations, Sanofi
Phone: 800-633-1610
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Physician assessment: Percentage (%) change from baseline in Eczema Area and Severity Index (EASI) score at Week 4, Week 16 and Week 52; Physician assessment: Percentage (%) of participants with EASI-50 at 4, 16, 52 weeks; Physician assessment: Percentage (%) of participants with EASI-75 at 4, 16, 52 weeks; Physician assessment: Percentage (%) of participants with EASI-90 at 4, 16, 52 weeks; Participant assessment: Change from baseline in Patient Oriented Eczema Measure (POEM) score at 4, 16, 52 weeks; Participant assessment: Percentage (%) of participants with a ≥ 6-point improvement from bas...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.